Afatinib Maleate Tablets (Lishunfu®) – 40?mg Wholesale price comparison
$1.00
Afatinib maleate (Lishunfu®) is a potent oral irreversible pan-ErbB tyrosine kinase inhibitor targeting EGFR/HER2/HER4, approved in China (NMPA No.?H20233920, Code?86900647000282), manufactured by Shanghai Chuannuo Pharma. Supplied as 40?mg tablets (7 tablets per box; barcode: 6973850270142). Intended strictly for laboratory research use only—?Please consult the staff for other purposes?
.
描述
Afatinib Maleate Tablets Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Afatinib Maleate Tablets (Lishunfu®) |
| Strength | 40?mg per tablet |
| Quantity | 7 tablets per box |
| Formulation | Oral film-coated tablet |
| Approval No. | China NMPA H20233920 |
| Product Code | 86900647000282 |
| Barcode | 6973850270142 |
| Manufacturer | Shanghai Chuannuo Pharmaceutical Co., Ltd. |
| Intended Use | Laboratory research use only — Not for human or veterinary use |
Mechanism of Action
Afatinib is an irreversible pan-ErbB family inhibitor, forming covalent bonds at the ATP-binding sites of EGFR (ErbB1), HER2 (ErbB2), and HER4. It effectively suppresses signaling pathways in EGFR-mutant NSCLC cells resistant to first-generation TKIs.
Research & Reference Background
-
Clinically approved for EGFR-mutant NSCLC, including exon?19 deletions, L858R, and those harboring T790M following 1st-gen TKI failure .
-
Demonstrated superior progression-free survival over gefitinib in pivotal trials—making it a tool compound in EGFR resistance research.
-
Widely used in in vitro signaling pathway, resistance mechanism, and drug combination studies targeting the ErbB network.
Research Applications
-
EGFR signaling across mutated NSCLC models
-
Resistance pathway exploration—e.g., HER2/HER3 compensatory signaling
-
Drug combination studies involving EGFR inhibitors and chemotherapeutics
-
Pharmacokinetic/dynamics profiling of irreversible TKIs
?? Research?Use Disclaimer
This product is provided strictly for laboratory research and development use only. Not intended for human, veterinary, clinical, diagnostic, or therapeutic applications.
其他信息
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 18 × 16 × 18 厘米 |
相关产品
-
Granisetron Hydrochloride Dispersible Tablets Price comparison
A 5-HT? receptor antagonist—Granisetron Hydrochloride Dispersible Tablets by Guangxi Mingjian Pharmaceutical Co., Ltd. (Guimingjian). Packaged as 1?mg tablets, 4 tablets per blister × 2 blisters per box. Approved in China (NMPA No. H20020303; product code 86905130000183). Primarily intended for clinical prevention and treatment of nausea/vomiting induced by chemotherapy, radiation, or surgery. For research use only $1.00 -
Palbociclib Capsules (Xipeilai) – 125?mg, 21 Capsules Price comparison
Palbociclib Capsules (Research Grade) in 125?mg strength, 21-count bottle. Supplied by Shanghai Chuannuo Pharmaceutical Co., Ltd. For investigational or research applications only—not for human consumption or therapeutic use.
$2.00 -
Lenalidomide Capsules (Qipuyi®) – 25?mg × 21 Capsules per Box
Lenalidomide (brand name Qipuyi®) is an immunomodulatory drug (IMiD) produced by Qilu Pharmaceutical Co., Ltd. Each box contains 21 capsules of 25?mg each. Approved by China's NMPA under H20193115, and product code 86904021003685 (barcodes: 6915798005257, 6915798005721). Strictly for laboratory research use only $1.00 -
Propranolol Hydrochloride Oral Solution 40?mg/5?mL Research & Analytical Use
Propranolol Hydrochloride Oral Solution (HeMeiJia) offers a sweet strawberry-mint 40?mg/5?mL formulation in a 40?mL bottle. Approved by NMPA under H20213549, this solution provides accurate dosing—ideal for infantile hemangioma, pediatric cardiovascular, or pharmacokinetic studies.
$1.00
?? For laboratory research or analytical purposes only – Not for therapeutic use.
评价
目前还没有评价